Evidence map›Paper›PMID 29848367›Full record

ArticleArthritis research & therapy2018

Transcription factor motif enrichment in whole transcriptome analysis identifies STAT4 and BCL6 as the most prominent binding motif in systemic juvenile idiopathic arthritis.

Boris Hügle, Anastasia Schippers, Nadine Fischer, Kim Ohl, Bernd Denecke, Fabio Ticconi, Bas Vastert, Ivan G Costa, Johannes-Peter Haas, Klaus Tenbrock

Open access · goldAbstract read
In one paragraph

Article in Arthritis research & therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Boris HügleGerman Center for Pediatric and Adolescent Rheumatology, Gehfeldstrasse 24, 82467, Garmisch-Partenkirchen, Germany. huegle.boris@rheuma-kinderklinik.de.ORCID 0000-0003-1145-6719
Anastasia SchippersDepartment of Pediatrics, Universitätsklinikum Aachen, Aachen, Germany.
Nadine FischerGerman Center for Pediatric and Adolescent Rheumatology, Gehfeldstrasse 24, 82467, Garmisch-Partenkirchen, Germany.
Kim OhlDepartment of Pediatrics, Universitätsklinikum Aachen, Aachen, Germany.
Bernd DeneckeDepartment of Pediatrics, Universitätsklinikum Aachen, Aachen, Germany.
Fabio TicconiIZKF Research Group Bioinformatics, RWTH Aachen Medical Faculty, Aachen, Germany.
Bas VastertUniversity Medical Center Utrecht, Utrecht, Netherlands.
Ivan G CostaIZKF Research Group Bioinformatics, RWTH Aachen Medical Faculty, Aachen, Germany.
Johannes-Peter HaasGerman Center for Pediatric and Adolescent Rheumatology, Gehfeldstrasse 24, 82467, Garmisch-Partenkirchen, Germany.
Klaus TenbrockDepartment of Pediatrics, Universitätsklinikum Aachen, Aachen, Germany.
Universitätsklinikum Aachen · DEGerman Center for Pediatric and Adolescent Rheumatology · DERWTH Aachen University · DEUniversity Medical Center Utrecht · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe term systemic juvenile idiopathic arthritis (sJIA) describes an autoinflammatory condition characterized by arthritis and severe systemic inflammation, which in later stages can transform into interleukin (IL)-17-driven autoimmune arthritis. IL-1 antagonists have been used with good efficacy in the early stages of sJIA.

methodsA whole transcriptome analysis of peripheral blood RNA samples was performed in six patients with sJIA and active systemic disease, before initiating treatment with the IL-1β receptor antagonist anakinra, and after induction of inactive disease, compared with a single-sample control cohort of 21 patients in several clinical stages of sJIA activity. Whole transcriptomes were compared longitudinally and interindividually including gene ontology and motif enrichment analysis of differentially expressed genes.

resultsThere were 741 transcripts were identified using a threshold with a p value <0.01 and a fold change > 2. HLADRB1 and CD74 were identified as the most strongly upregulated genes in inactive compared to active disease; CD177 expression was significantly enhanced in active disease compared to inactive disease. Motif enrichment analysis revealed STAT4, BCL6, and STAT3 as the most prominent transcription factors that were present during active disease. In addition, strong upregulation of the major histocompatability complex II (MHCII) ligand CD74 was found in both active and inactive sJIA compared to healthy controls.

conclusionUsing transcription factor motif enrichment, this study identifies novel putative pathways in sJIA (STAT4, BCL6) implicating B cell activation at an earlier stage than predicted in refractory disease. The implication of BCL-6 dependent pathways argues for occurrence of autoimmunity early within the process of sJIA chronification. Transcriptional regulation of HLA-DRB1, a recently described independent genetic risk factor, in combination with its cooperating partner CD74 in patients where sJIA is confirmed, supports pathogenic involvement in alterations in antigen presentation during sJIA.

Indexed as

AdolescentArthritis, JuvenileChildChild, PreschoolCohort StudiesFemaleGene Expression ProfilingHumansInfantLongitudinal StudiesMaleProtein BindingProto-Oncogene Proteins c-bcl-6Retrospective StudiesSTAT4 Transcription FactorTranscription FactorsBCL6 protein, humanProto-Oncogene Proteins c-bcl-6STAT4 protein, humanSTAT4 Transcription FactorTranscription FactorsCD177CD74HLA-DRB1Juvenile idiopathic arthritisJuvenile systemic arthritisRNA expression

Identifiers

PMID29848367
PMCPMC5977738
OpenAlexW2806330127

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.